Sir,
We read with interest the article of Leung et al (2007) describing a reduced relapse rate after autologous HSCT in patients with an inhibitory KIR–HLA mismatch treated with autologous transplantation for non-Hodgkin's lymphoma or solid tumour. The analysis was performed after several recent publications indicated a reduced relapse rate in patients treated by allogeneic HSCT (by the same group (Leung et al, 2005) and others (Hsu et al, 2005)) in the presence of a mismatch between donor inhibitory KIR and patient HLA.
The manuscript prompted us to analyse the outcome after autologous transplantations carried out between 1997 and 2006 at our centre. Patients were included if HLA typing allowed unequivocal deduction of the KIR-ligand status, and were grouped according to the presence or absence of KIR ligands, without taking into account inhibitory KIR. This type of approach is generally chosen for retrospective studies (Miller et al, 2007), as population frequencies of KIR gene distribution indicate that virtually all Caucasians possess and express KIR2DL1 and KIR2DL2/3 and only a minority do not possess or express KIR3DL1. Therefore, grouping according to KIR ligands should correctly classify the vast majority of patients regarding an inhibitory KIR/HLA mismatch (in the publication by Leung, 1 out of 16 patients would have been misclassified using this approach).
Outcome of 67 autologous transplants for solid tumour (N=23) or lymphoma (N=44) was analysed. In 21 patients, grafts were depleted from tumour cells and T cells by CD34 selection. Absence of KIR ligands had no effect on disease-free survival (DFS) (relative risk (RR) 1.03 vs patients with all KIR ligands, P=0.91) or disease relapse (RR 1.24, P=0.23; Figure 1). Similar results were seen when the analysis was restricted to patients receiving T-cell-depleted transplants (RR for DFS 1.08, P=0.88; RR for relapse 1.15, P=0.79). Excluding patients missing Bw4 (the ligand for KIR3DL1, the only inhibitory KIR absent in a significant proportion of Caucasians), the relative risks for DFS and relapse were 1.15 (P=0.59) and 1.36 (P=0.28) for missing ligand patients.
In conclusion, we were not able to show a missing KIR-ligand effect in our population of autologous HSCT recipients. One caveat of our approach is that a missing KIR ligand does not imply an inhibitory KIR/HLA mismatch, however, restriction of analysis to the almost universally expressed KIR2D did not show significant differences. We therefore believe that while the data presented by Leung et al (2007) are intriguing, they should be confirmed in large studies.
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K, O'Reilly RJ, Horowitz MM, Dupont B (2005) Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 105: 4878–4884
Leung W, Handgretinger R, Iyengar R, Turner V, Holladay MS, Hale GA (2007) Inhibitory KIR–HLA receptor–ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphoma. Br J Cancer 97: 539–542
Leung W, Iyengar R, Triplett B, Turner V, Behm FG, Holladay MS, Houston J, Handgretinger R (2005) Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J Immunol 174: 6540–6545
Miller JS, Cooley S, Parham P, Farag SS, Verneris MR, McQueen KL, Guethlein LA, Trachtenberg EA, Haagenson M, Horowitz MM, Klein JP, Weisdorf DJ (2007) Missing KIR ligands are associated with less relapse and increased graft-vs-host disease (GVHD) following unrelated donor allogeneic HCT. Blood 109: 5058–5061
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Stern, M., Paulussen, M., Rischewski, J. et al. Missing ligand model in autologous stem cell transplantation. Br J Cancer 98, 852–853 (2008). https://doi.org/10.1038/sj.bjc.6604153
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6604153